1. Global tuberculosis report 2016 / World Health Organization. - Geneva : World Health Organization Publ., 2016. - 214 p.
2. Гуревич, Г. Л. Туберкулез: возбудитель, патогенез, риск заболевания, эпидемиология / Г. Л. Гуревич, О. М. Калечиц // Мир медицины. - 2012. - № 5. - С. 3-4.
3. World Health Organization, the HWO/IUATLD Anti-tuberculosis drug resistance in the world: The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Anti-tuberculosis Drug Resistance in the World: Forth Global Report. WHO/HTM/TB/2008.394. - Geneva : World Health Organization Publ., 2008. - 64 p.
4. Влияние множественной лекарственной устойчивости на эффективность лечения больных туберкулезом / Е. М. Скрягина [и др.] // Рецепт. - 2010. - № 1. - С. 61-66.
5. Multidrug-resistant tuberculosis in Belarus: the size of the problem and associated risk factors / A. Skrahina [et al.] // Bull. of the World Health Organization. - 2013. - Vol. 91, N 1. - P. 36-45.
6. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes / D. Falzon [et al.] // Europ. Respiratory J. - 2013. - Vol. 42, N 1. - P. 156-168.
7. Drug resistance beyond extensively drug resistant tuberculosis: individual patient data meta-analysis / G. B. Migliori [et al.] // Europ. Respiratory J. - 2013. - Vol. 42, N 1. - P. 169-179.
8. Frequency of recurrence among MDR-TB cases «successfully» treated with standardised short-course chemotherapy / G. B. Migliori [et al.] // Intern. J. of Tuberculosis and Lung Disease. - 2002. - Vol. 6, N 10. - P. 858-864.
9. Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation / R. Diel [et al.] // Europ. Respiratory J. - 2014. - Vol. 43, N 2. - P. 554-565.
10. Caminero, J. A. Classification of antituberculosis drugs: a new proposal based on the most recent evidence / J. A. Caminero, A. Scardigli // European Respiratory J. - 2014. - Vol. 46, N 4. - P. 887-893.
11. Sotgiu, G. Linezolid to treat MDR-/XDR-Tuberculosis: available evidence and future scenarios / G. Sotgiu, E. Pontali, G. B. Migliori // Europ. Respiratory J. - 2015. - Vol. 45, N 1. - P. 25-29.
12. Tuberculosis: cost of illness in Germany / R. Diel [et al.] // Europ. Respiratory J. - 2012. - Vol. 40, N 1. - P. 143-151.
13. First tuberculosis cases in Italy resistant to all tested drugs / G. B. Migliori [et al.] // Eurosurveillance (Weekly releases). - 2007. - Vol. 12, N 5. - E070517.1.
14. Bedaquiline and MDR-TB: a systematic and critical analysis of the evidence / E. Pontali [et al.] // Europ. Respiratory J. - 2016. - Vol. 47, N 2. - P. 394-402.
15. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update / D. Falzon [et al.] // Europ. Respiratory J. - 2011. - Vol. 38, N 3. - P. 516-528.
16. Caminero, J. A. Classification of antituberculosis drugs: a new proposal based on the most recent evidence / J. A. Caminero, A. Scardigli // Europ. Respiratory J. - 2015. - Vol. 46, N 4. - P. 887-893.
17. Bedaquiline in the treatment of multi- and extensively drug-resistant tuberculosis / A. S. Pym [et al.] // Europ. Respiratory J. - 2016. - Vol. 47, N 2. - P. 564-574.
18. The diarylquinoline TMC207 for multidrug-resistant tuberculosis / A. H. Diacon [et al.] // New England J. of Medicine. - 2009. - Vol. 360, N 23. - P. 2397-2405.
19. Multidrug-resistant tuberculosis and culture conversion with bedaquiline / A. H. Diacon [et al.] // New England J. of Medicine. - 2014. -Vol. 371, N 8. - P. 723-732.
20. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort / L. Guglielmetti [et al.] // Clinical Infectious Diseases. - 2015. - Vol. 60, N 2. - P. 188-194.
21. Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis / N. Ndjeka [et al.] // Intern. J. of Tuberculosis and Lung Disease. - 2015. - Vol. 19, N 8. - P. 979-985.
22. Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use / S. Tiberi [et al.] // Europ. Respiratory J. - 2014. - Vol. 43, N 1. - P. 289-292.
23. First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline / M. Tadolini [et al.] // Europ. Respiratory J. - 2016. - Vol. 48, N 3. - P. 935-938.
24. Wallis, R. S. Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine / R. S. Wallis // Europ. Respiratory J. - 2016. - Vol. 48, N 5. - P. 1526-1527.
25. Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine / M. Tadolini [et al.] // Europ. Respiratory J. - 2016. - Vol. 48, N 5. - P. 1527-1529.
26. Human but not murine multipotent mesenchymal stromal cells exhibit broad-spectrum antimicrobial effector function mediated by indoleamine 2,3-dioxygenase / R. Meisel [et al.] // Leukemia. - 2011. - Vol. 25, N 4. - P. 648-654.
27. Mesenchymal stem cells improve murine acute coxsackievirus B3-induced myocarditis / S. Van Linthout [et al.] // Europ. Heart J. - 2010. - Vol. 32, N 17. - P. 2168-2178.
28. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis / Sh. H. J. Mei [et al.] // Amer. J. of Respiratory and Critical Care Medicine. - 2010. - Vol. 182, N 8. - P. 1047-1057.
29. Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37 / A. Krasnodembskaya [et al.] // Stem Cells. - 2010. - Vol. 28, N 12. - P. 2229-2238.
30. Stem cell transplantation: the lung barrier / S. Schrepfer [et al.] // Transplantation Proc. - 2007. - Vol. 39, N 2. - P. 573-576.
31. Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone / R. Sackstein [et al.] // Nature Medicine. - 2008. - Vol. 14, N 2. - P. 181-187.
32. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. / J. Gao [et al.] // Cells Tissues Organs. - 2001. - Vol. 169, N 1. - P. 12-20.
33. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. / I. M. Barbash [et al.] // Circulation. - 2003. - Vol. 108, N 7. - P. 863-868.
34. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6 / R. H. Lee [et al.] // Cell Stem Cell. - 2009. - Vol. 5, N 1. - P. 54-63.
35. Therapeutic potential of mesenchymal stem cells for severe acute lung injury / M. A. Matthay [et al.] // Chest. - 2010. - Vol. 138, N 4. - P. 965-972.
36. Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxininduced acute lung injury in mice / N. Gupta [et al.] // J. of Immunology. - 2007. - Vol. 179, N 3. - P. 1855-1863.
37. Therapeutic effects of bone marrow-derived mesenchymal stem cells engraftment on bleomycin-induced lung injury in rats / F. Zhao [et al.] // Transplantation Proc. - 2008. - Vol. 40, N 5. - P. 1700-1705.
38. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects / L. A. Ortiz [et al.] // Proc. of the Nat. Acad. of Sciences. - 2003. - Vol. 100, N 14. - P. 8407-8411.